Yttrium-based therapy for neuroendocrine tumors

Research output: Contribution to journalArticlepeer-review


Peptide receptor radionuclide therapy with 90Y-peptides is generally well tolerated. Acute side effects are usually mild; some are related to the coadministration of amino acids and others to the radiopeptide itself. Chronic and permanent effects on target organs, particularly kidneys and bone marrow, are generally mild if necessary precautions are taken. The potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumor masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most used radiopeptide in the first 8 to 10 years of experience.

Original languageEnglish
Pages (from-to)71-82
Number of pages12
JournalPET Clinics
Issue number1
Publication statusPublished - Jan 2014


  • Dosimetry
  • Neuroendocrine tumors
  • Peptide receptor radionuclide therapy
  • PRRT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation


Dive into the research topics of 'Yttrium-based therapy for neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this